Version 1
: Received: 8 May 2024 / Approved: 8 May 2024 / Online: 8 May 2024 (16:07:57 CEST)
How to cite:
Krishnan, A. V.; Freniere, V.; Sahni, R.; Vargas Chaves, D. P.; Krishnan, S. S.; Savva, D.; Krishnan, U. S. Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants. Preprints2024, 2024050487. https://doi.org/10.20944/preprints202405.0487.v1
Krishnan, A. V.; Freniere, V.; Sahni, R.; Vargas Chaves, D. P.; Krishnan, S. S.; Savva, D.; Krishnan, U. S. Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants. Preprints 2024, 2024050487. https://doi.org/10.20944/preprints202405.0487.v1
Krishnan, A. V.; Freniere, V.; Sahni, R.; Vargas Chaves, D. P.; Krishnan, S. S.; Savva, D.; Krishnan, U. S. Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants. Preprints2024, 2024050487. https://doi.org/10.20944/preprints202405.0487.v1
APA Style
Krishnan, A. V., Freniere, V., Sahni, R., Vargas Chaves, D. P., Krishnan, S. S., Savva, D., & Krishnan, U. S. (2024). Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants. Preprints. https://doi.org/10.20944/preprints202405.0487.v1
Chicago/Turabian Style
Krishnan, A. V., Dimitrios Savva and Usha S Krishnan. 2024 "Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants" Preprints. https://doi.org/10.20944/preprints202405.0487.v1
Abstract
This is a single center retrospective study to assess safety and tolerability of continuous inhaled iloprost use as rescue therapy for refractory pulmonary hypertension (PH) in critically ill neonates and infants. Retrospective chart review was performed on 58 infants and data was collected at baseline, 1, 6, 12, 24, 48, and 72 hours of iloprost initiation. Primary outcomes were change in heart rate (HR), fraction of inspired oxygen (FiO2), mean airway pressures (MAP), blood pressure (BP) and oxygenation index (OI). Secondary outcomes were need for extracorporeal membrane oxygenation (ECMO) and death. 51 patients treated for > 6 hours were analyzed in 2 age groups, neonate (≤28 days: n=32) and infant (29-365 days: n=19). FiO2 (p
Medicine and Pharmacology, Pediatrics, Perinatology and Child Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
